Drug Trial Radar · NCT00954447
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Dec 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,263
Actual
Start
Aug 2009
Primary completion
Sep 2011
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Aug 7, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Conditions
- Diabetes Mellitus, Type 2
Interventions
PlaceboDrug
Placebo, identical to Linagliptin tablet
LinagliptinDrug
intended final marketed dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c After 24 WeeksTime frame: Baseline and 24 weeks
Locations
169 sites in 19 countries. Site status is shown where the registry gives one.
1218.36.01043 Boehringer Ingelheim Investigational Site
Escondido, California
1218.36.01051 Boehringer Ingelheim Investigational Site
Escondido, California
1218.36.01065 Boehringer Ingelheim Investigational Site
Fresno, California
1218.36.01021 Boehringer Ingelheim Investigational Site
Greenbrae, California
1218.36.01013 Boehringer Ingelheim Investigational Site
Los Angeles, California
1218.36.01048 Boehringer Ingelheim Investigational Site
Los Angeles, California
1218.36.01058 Boehringer Ingelheim Investigational Site
San Diego, California
1218.36.01008 Boehringer Ingelheim Investigational Site
Santa Ana, California
1218.36.01056 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut
1218.36.01054 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1218.36.01035 Boehringer Ingelheim Investigational Site
Inverness, Florida
1218.36.01010 Boehringer Ingelheim Investigational Site
Miami, Florida
1218.36.01042 Boehringer Ingelheim Investigational Site
New Port Richey, Florida
1218.36.01063 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida
1218.36.01037 Boehringer Ingelheim Investigational Site
Ponte Vedra, Florida
1218.36.01032 Boehringer Ingelheim Investigational Site
Saint Cloud, Florida
1218.36.01049 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
1218.36.01036 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1218.36.01047 Boehringer Ingelheim Investigational Site
Decatur, Georgia
1218.36.01009 Boehringer Ingelheim Investigational Site
Roswell, Georgia
1218.36.01055 Boehringer Ingelheim Investigational Site
Honolulu, Hawaii
1218.36.01014 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1218.36.01011 Boehringer Ingelheim Investigational Site
Paducah, Kentucky
1218.36.01034 Boehringer Ingelheim Investigational Site
City of Saint Peters, Missouri
1218.36.01040 Boehringer Ingelheim Investigational Site
Kansas City, Missouri
1218.36.01029 Boehringer Ingelheim Investigational Site
St Louis, Missouri
1218.36.01018 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
1218.36.01053 Boehringer Ingelheim Investigational Site
New Hartford, New York
1218.36.01006 Boehringer Ingelheim Investigational Site
Burlington, North Carolina
1218.36.01025 Boehringer Ingelheim Investigational Site
Hickory, North Carolina
1218.36.01005 Boehringer Ingelheim Investigational Site
Statesville, North Carolina
1218.36.01015 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1218.36.01039 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma
1218.36.01019 Boehringer Ingelheim Investigational Site
Altoona, Pennsylvania
1218.36.01012 Boehringer Ingelheim Investigational Site
Norristown, Pennsylvania
1218.36.01004 Boehringer Ingelheim Investigational Site
Greer, South Carolina
1218.36.01020 Boehringer Ingelheim Investigational Site
Simpsonville, South Carolina
1218.36.01003 Boehringer Ingelheim Investigational Site
Kingsport, Tennessee
1218.36.01038 Boehringer Ingelheim Investigational Site
Dallas, Texas
1218.36.01016 Boehringer Ingelheim Investigational Site
Houston, Texas
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.